Kamis, 31 Juli 2014 Ebola virus economism hepatitis C neoliberalism pharmaceuticals Sovaldi No Treatment or Vaccine for Ebola, but a $1000 Pill for Hepatitis C The Ebola virus epidemic in West Africa continues to grow, and now appears to be the worst known epidemic of that disease to date. In the U...
Kamis, 24 Juli 2014 clinical trials evidence-based medicine Gilead Sovaldi Sovaldi, a Quantum Leap... Backwards to the Days Before Randomized Controlled Trials? The Sovaldi (sofosbuvir - Gilead) media circus is continuing. The New York Times just reported that sales of the new drug for hepatitis C w...
Jumat, 20 Juni 2014 anechoic effect clinical trials evidence-based medicine executive compensation Gilead health care prices manipulating clinical research Sovaldi Fourth Time is the (Anti)Charm? - UK NICE Highlights "Uncertainties in the Evidence Base" About Sovaldi As we have discussed, ( here , here and here ), while anger continues to build about the $1000/ pill price sought by Gilead for its new ant...
Rabu, 28 Mei 2014 evidence-based medicine Gilead health care prices manipulating clinical research Sovaldi You heard it here first Sovaldi - a "Revolution" in Clinical Care, or in Marketing and Public Relations? The continuing public discussion of the sky high price Gilead has set for Sovaldi (sofosbuvir,) its new antiviral drug for hepatitis C, cont...
Rabu, 07 Mei 2014 evidence-based medicine Gilead health care prices manipulating clinical research pharmaceuticals Sovaldi Some Authoritative Skepticism about the "Triumph" of Sovaldi to Add to Outrage about "Blood Money" Three weeks ago we posted about the continuing controversy over the stratospheric price of the new antiviral drug for hepatitis C (HCV), sof...
Rabu, 16 April 2014 conflicts of interest evidence-based medicine Gilead health care prices manipulating clinical research pharmaceuticals Sovaldi Knee Deep in the Hoopla - "A Triumph of Medical Technology" Sans Evidence of Superiority from Published Randomized Double Blind Controlled Trials With the publication of several new articles in the prestigious New England Journal of Medicine, the buzz about Sovaldi (sofosbuvir - Gilead...